ACHE and early-onset autosomal dominant Alzheimer disease: Synthesized AChE inhibitors are promising candidates for the development of new drugs for Alzheimer’s disease, as they can target multiple aspects of the disease pathogenesis and offer better efficacy and safety profiles than the currently available drugs.